RHON-KLINIKUM AG reported solid financial results for 2025, meeting its targets despite challenging health policy and economic conditions. The group treated 938,650 patients across its clinics and medical care centers, representing a 2.5% increase from the previous year, while consolidated revenues grew organically by 6.8% to €1,704.7 million. Dr. Stefan Stranz, a member of the Board of Management, stated that the group's economic development remains solid and positive given the tense situation of hospitals and industry development in Germany. He emphasized the importance of cooperation within the corporate group with ASKLEPIOS as a key success factor in an environment characterized by medical progress, increasing demand for high-quality care, and economic pressure.
EBITDA for 2025 amounted to €105.9 million, while consolidated profit decreased to €36.3 million due to higher depreciation and impairment of fixed assets as well as declining interest rates. The Supervisory Board and Board of Management have proposed a dividend of €0.20 per share. Throughout 2025, RHON-KLINIKUM AG launched further clinic development measures and added new care offerings at all locations to expand outpatient and inpatient treatment. The two university locations in Gießen and Marburg combined their strengths in a joint breast center, setting a new standard in oncological care in Hesse.
The company's financial stability enables targeted investments in medical high-tech, as noted by Dr. Gunther K. WeiB, another Board of Management member, who stated this sends a strong signal for the dynamic and technological development of their facilities. Specific investments included a new laboratory line in Giessen, new cardiac catheter technologies and a 3 Tesla magnetic resonance tomograph in Marburg, and a radiotherapy system for cancer treatment in Bad Berka. The company has also implemented photon counting computer tomography technology, becoming the only hospital group with three of the latest generation systems in use, with further investments planned. The Annual Report 2025 is published on the Internet at https://www.rhoen-klinikum-ag.com.
For 2026, the group expects revenues of approximately €1.7 billion within a range of plus or minus 5%, with EBITDA projected between €110 million and €125 million. Management also considers non-financial performance indicators including number of cases and cost weights, which are expected to see moderate increases. This forecast reflects heightened regulatory interference by the German legislator and political implementation of necessary hospital reform, though the outlook faces uncertainties from global crises affecting prices and supply chains, plus potential regulatory measures impacting medical service remuneration structures.
